Article:Prevalence, Risk Factors, and Pathophysiology of Dysglycemia among People Living with HIV in Sub-Saharan Africa (5989168)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q56978971. Its title is Prevalence, Risk Factors, and Pathophysiology of Dysglycemia among People Living with HIV in Sub-Saharan Africa and the publication date was 2018-05-23. The initial author is Benson Njuguna.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Journal of Diabetes Research

Prevalence, Risk Factors, and Pathophysiology of Dysglycemia among People Living with HIV in Sub-Saharan Africa

  • Benson Njuguna
  • Jepchirchir Kiplagat
  • Gerald S. Bloomfield
  • Sonak D. Pastakia
  • Rajesh Vedanthan
  • John R. Koethe

1Moi Teaching and Referral Hospital, P.O. Box 4606-30100, Eldoret, Kenya

2Academic Model Providing Access to Healthcare (AMPATH), P.O. Box 4606-30100, Eldoret, Kenya

3Duke Clinical Research Institute, Duke Global Health Institute, Duke University, 2400 Pratt Street, Durham, NC 27710, USA

4Purdue University College of Pharmacy, P.O. Box 5760 Eldoret 30100, Kenya

5Zena and Michael A. Wiener Cardiovascular Institute, Department of Medicine and Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, P.O. Box 1030, New York, NY 10029, USA

6Division of Infectious Diseases, Vanderbilt University Medical Center, A2200-MCN 1161 21st Avenue South, Nashville, TN 37232, USA

Publication date (collection): /2018

Publication date (epub): 5/2018

Abstract

Objective

To review available literature on the prevalence, risk factors, pathophysiology, and clinical outcomes of dysglycemia among people living with HIV (PLHIV) in sub-Saharan Africa (SSA).

Methods

Database search on PUBMED for eligible studies describing the prevalence, risk factors, pathophysiology, or clinical outcomes of dysglycemia in SSA PLHIV.

Results

Prevalence of diabetes mellitus (DM) and pre-DM among SSA PLHIV ranged from 1% to 26% and 19% to 47%, respectively, in 15 identified studies. Older age and an elevated body mass index (BMI) were common risk factors for dysglycemia. Risk factors potentially more specific to PLHIV in SSA included exposure to older-generation thymidine analogues or protease inhibitors, malnutrition at ART initiation, a failure to gain fat mass on treatment, and elevated serum lipids. There is evidence of higher nephropathy and neuropathy rates among PLHIV in SSA with comorbid DM compared to HIV-negative individuals with DM.

Conclusion

There is a need for longitudinal studies to enhance understanding of the risk factors for dysglycemia among PLHIV in SSA, further research into optimal therapies to reduce pre-DM progression to DM among SSA PLHIV, and studies of the burden and phenotype of diabetic complications and other health outcomes among PLHIV with comorbid DM in SSA.

Paper

1. Introduction

Sub-Saharan Africa (SSA) accounts for 80% of the global HIV burden and 60% of new HIV infections [[1]]. Wide-scale adoption of combination antiretroviral therapy (ART) has decreased infection-related mortality among people living with HIV (PLHIV) and increased life expectancy, but this success is tempered by an increasing burden of noncommunicable diseases (NCDs) [[2], [3]]. Studies of US patient cohorts found PLHIV had as high as a fourfold elevated risk of diabetes mellitus (DM) as compared to HIV-negative persons after adjusting for other risk factors [[4], [5]]. Current evidence, predominantly from US and European cohorts, indicates this elevated risk of dysglycemia, encompassing both DM and prediabetes (pre-DM; defined as impaired fasting glucose (IFG) or impaired glucose tolerance (IGT)), in PLHIV likely reflects a mix of the effects of HIV per se, chronic inflammation, and some ART agents on glucose metabolism, as well as potentially disproportionate contributions of obesity and older age to DM risk among PLHIV compared to the general population [[6], [7]].

The majority of studies on dysglycemia in PLHIV come from high-income country settings (HIC), and as a result, the extent to which identified risk factors associated with dysglycemia burden, morbidity, and mortality can be extrapolated to SSA populations is unclear. PLHIV in SSA have several characteristics that may lead to differences in dysglycemia risk compared to PLHIV in HIC. These include (i) higher levels of inflammation biomarkers such as high sensitivity C-reactive protein (hsCRP) and fibrinogen in HIV-negative SSA populations compared to HIC populations potentially reflecting a higher background inflammatory state [[8]], (ii) ongoing or recent use of older generation ART agents in SSA associated with the development of lipodystrophy and dysglycemia (e.g., thymidine analogues), (iii) limited access to DM screening, prevention, and treatment services in SSA [[9]], and (iv) a lower prevalence of traditional risk factors for DM such as advanced age, obesity, dyslipidemia, and sedentary lifestyles [[10][13]].

HIV and dysglycemia are independent risk factors for cardiovascular disease (CVD) and CVD events, such as stroke and myocardial infarction, chronic kidney disease (CKD), neurocognitive decline, and other comorbidities [[14][20]]. Pre-DM not only predicts future development of DM, with 4–20% of pre-DM progressing to DM annually in the general population if no pharmacological or nonpharmacological interventions are made, but it is also an independent risk factor for CVD [[21]]. Consequently, knowledge of the risk factors and burden of dysglycemia among SSA PLHIV is crucial in identifying gaps in care and future research priorities. We undertook this review to describe the relatively limited literature on the prevalence, risk factors, pathophysiology, and clinical outcomes of dysglycemia among SSA PLHIV and highlight the research gaps and high-priority areas for future research.

2. Methods

We searched PUBMED using the keywords “diabetes,” “insulin resistance,” “glucose intolerance,” “dysglycemia,” “sub-Saharan Africa,” “HIV,” “prevalence,” “pathophysiology,” “risk factors,” “mortality,” “morbidity,” and their related terms. Studies were considered for inclusion if they were original research articles and described any of the following: the prevalence, risk factors, pathophysiology, or clinical outcomes of dysglycemia (CVD-related morbidity and mortality, and microvascular or macrovascular complications) in PLHIV in SSA. Additionally, we screened the reference lists of retrieved articles for other sources. Articles published through August 2017 were considered, with no restriction on the start date. We excluded conference abstracts, narrative or systematic reviews, and articles not in English. Results were summarized descriptively in narrative and tabular form. No additional statistical methods were deployed as we did not pool data.

3. Results

3.1. Prevalence of Dysglycemia among PLHIV in SSA

Prevalence data came from 15 studies across 8 countries (Figure 1), highlighting both the dearth of data and variability in the study population. The prevalence of DM among PLHIV ranged from 1% to 26%, while that of pre-DM (IFG or/and IGT) was 19% to 47%, in our reviewed studies [[22][36]]. There was, however, wide variability in the definition of the population studied, methodology employed, definition of pre-DM, and diagnostic criteria used for DM or pre-DM (Table 1).

Ngatchou et al. reported the highest DM (26%) and pre-DM (47%) prevalence in a cohort of 108 ART-naive PLHIV in Cameroon that was predominantly (74%) female, had a mean age of 39 years, and had a mean BMI of 25.1 kg/m2 [[34]]. Additional characteristics of this population were a mean waist circumference of 81 cm and waist-hip ratio of 0.8, both of which were lower than in HIV-negative controls, who had a much lower prevalence (1%) of DM.

Four studies compared dysglycemia (DM and pre-DM) prevalence between PLHIV on ART versus ART-naive and reported differing results [[24], [26][28]]. Levitt et al. [[27]] found progressively higher prevalence of dysglycemia in South African ART-naive PLHIV (22%), PLHIV on 1st line ART (26%), and PLHIV on 2nd line ART (37%). Maganga et al. [[28]] also reported higher dysglycemia among Tanzanian PLHIV on ART for at least 2 years (33%) compared to ART-naive PLHIV (8%). In contrast, Dave et al. [[24]] found a nonsignificant difference in dysglycemia prevalence between South African PLHIV on ART for at least 6 months (26%) compared to ART-naive PLHIV (22%) while Kagaruki et al. [[26]] noted a slightly higher DM prevalence in ART-naive PLHIV (5%) compared to PLHIV on ART (4%). The difference in these findings may partially be explained by the different median durations on ART, for example, 56 versus 16 months in the study by Maganga et al. and Dave et al., respectively, while the duration on ART was not specified in the study by Kagaruki et al.

Five studies compared the prevalence of dysglycemia between PLHIV and HIV-negative controls [[22], [28], [32][34]]. A trend toward a higher prevalence of dysglycemia among PLHIV was noted compared to HIV-negative individuals although statistically significant differences were found in only two of the studies [[28], [34]]. A major limitation of the above comparisons was the lack of matching in the control group which led to subsequent between-group differences in potential risk factors for dysglycemia. For instance, in the study by Maganga et al., lower mean age and less central obesity among HIV-negative controls compared to PLHIV at baseline was noted but not adjusted for in the prevalence comparison [[28]].

3.2. Risk Factors for Dysglycemia in PLHIV

Commonly identified risk factors for dysglycemia in our reviewed studies included older age in six studies [[23][25], [27], [28], [31]] and elevated BMI in three studies [[23], [25], [28]]. Both age and elevated BMI are considered traditional risk factors for dysglycemia in the general population, and they remain relevant in the PLHIV population [[6]]. Male gender [[23], [24]], long-term ART use [[28], [31]], efavirenz versus nevirapine use [[24], [37]], and higher CD4 count [[24], [28]] were identified as risk factors in two studies each. Individual studies found associations between dysglycemia in PLHIV and protease inhibitor use [[23]], stavudine use [[37]], zidovudine use [[37]], and female sex [[27]]. Of note, we did not find studies in SSA PLHIV that identified an association between inflammation and dysglycemia, yet, from HIC studies, it is evident that markers of inflammation are chronically elevated in both ART-naive and ART-treated PLHIV [[38][41]] and are potentially related to dysglycemia incidence [[42], [43]].

3.3. Pathophysiology of Dysglycemia in PLHIV in SSA

Obesity prevalence is rising in the general population and among PLHIV in SSA [[13], [44], [45]], and several studies have demonstrated the steep rise in DM risk accompanying higher BMI values as also reported in US and European cohorts [[6], [23], [46][49]]. However, there is a clear subset of PLHIV in SSA who develop IFG and DM in the absence of high BMI, though the etiology and the underlying bioenergetics pathway changes of this nonobese DM phenotype are unclear. In South Africa, IFG prevalence was 21% among PLHIV and did not correlate with central obesity [[27]]. Similarly, BMI did not correlate with insulin sensitivity in a Rwandan PLHIV cohort with a high prevalence of IFG [[32]]. In a Tanzanian study, the prevalence of DM was over threefold higher in PLHIV compared to HIV-negative individuals, and this difference could not be accounted for by differences in age, gender, BMI, or socioeconomic status [[28]]. Lastly, in a comparative study in Israel, DM prevalence was higher in Ethiopian immigrant PLHIV (31%) than in native-Israeli PLHIV (4%), with Ethiopians more likely to develop DM at low BMI values [[50]].

The handful of studies of IFG and DM risk factors among PLHIV in SSA highlights potential pathophysiologic features which may contribute to the development of glucose intolerance in the absence of more widely recognized risk factors, such as obesity or advanced age. Circulating inflammatory cytokine levels are elevated in many PLHIV on ART in SSA, due in part to impaired mucosal defenses, chronic gastrointestinal enteropathy, and opportunistic infections, which may have a role in the development of dysglycemia [[51][53]]. Prior studies in PLHIV in the US and Europe have linked soluble inflammatory mediators (e.g., C-reactive protein (CRP) and interleukin-6 (IL-6)) to insulin resistance or incident DM [[42], [43]]. In two large PLHIV cohorts, enrollment CRP and IL-6 levels predicted incident DM several years prior to onset, and each doubling of enrollment IL-6 was associated with an approximately 30% increased risk of developing DM [[42]]. While prior studies in SSA have found elevated CRP, IL-6, and other markers of systemic inflammation which were associated with increased mortality and cardiovascular disease [[54][58]], there is a clear need for data on the relationship of inflammation with metabolic comorbidities. Furthermore, caution is warranted in extrapolating findings from US or European cohorts; a recent study of low BMI Zambian and Tanzanian PLHIV found pre-ART and on-ART serum CRP levels did not predict the risk of IFG and DM, though IL-6 and other cytokines were not measured [[59]].

A study from Ethiopia found elevated low-density lipoprotein (LDL) was independently associated with the development of DM in predominantly non-overweight/obese PLHIV [[31]]. In contrast, a second study from Ethiopia found total cholesterol (a measurement that incorporates LDL, high-density lipoprotein (HDL), and triglycerides), but not LDL alone, was associated with metabolic syndrome as defined by the National Cholesterol Education Program: Adult Treatment Panel III (ATP) criteria [[60]]. An association between LDL and ATP-defined metabolic syndrome was also not observed in a large multicenter study of PLHIV at 32 worldwide sites (though no sites in SSA were included) [[61]]. These conflicting results highlight the need for further investigation of the relationship between hyperlipidemia and glucose tolerance among PLHIV SSA, particularly given the lower BMI often present in this population. Studies early in the HIV epidemic found de novo hepatic lipogenesis was increased over threefold among PLHIV with recent weight loss compared to HIV-negative controls, in addition to accelerated lipolysis and failure to consume plasma free fatty acids [[62]]. There is evidence that excessive circulating free fatty acids and protein-bound lipids contribute to the development of other metabolic abnormalities. Persistently, high serum lipids are linked to the development of steatohepatitis in PLHIV in SSA and other regions, which can be accompanied by additional ectopic lipid deposits (e.g., intramyocellular or intramyocardial) and glucose intolerance [[63][69]].

While most patients gain weight after starting ART, particularly those with a lower pretreatment BMI [[70], [71]], the early recovery of adipose tissue may be unevenly distributed and can evolve into an abnormal repartitioning termed ‘lipodystrophy' [[72][79]]. Even in the absence of clinically apparent changes, radiographic studies have found a significantly lower percentage of extremity body fat in treated PLHIV compared to healthy controls, suggesting lipodystrophy represents a continuum and most PLHIV remain susceptible to some degree [[80]]. Several longitudinal studies from SSA demonstrate central fat accumulation and peripheral fat loss among PLHIV on ART [[81][83]]. The persistence of these changes in body habitus may have been exacerbated by older-generation nucleoside reverse transcriptase inhibitor (NRTI) use in some treatment programs after these agents had been largely replaced in US and European settings. Loss of limb fat, attributed to mitochondrial DNA polymerase γ inhibition and impaired respiratory chain efficiency in adipocytes, is more prevalent with older thymidine analogues (e.g., stavudine and zidovudine) compared to newer agents (e.g., lamivudine, abacavir, and tenofovir) [[84][86]]. Adipose tissue samples from lipoatrophic individuals treated with zidovudine or stavudine demonstrate higher macrophage infiltration and proinflammatory cytokine production; two features thought to contribute to adipocyte insulin resistance and altered lipid handling [[87][92]].

In a recent, large longitudinal study in Zambia and Tanzania of PLHIV who started ART at a low BMI, the risk of developing IFG or DM after treatment initiation was paradoxically highest among those with the lowest pre-ART hip circumference and body fat mass index [[59]]. Furthermore, the risk of diabetes was also inversely related to the change in BMI after 2-3 years of ART; patients who started ART with a low BMI and failed to gain weight were at a higher risk of dysglycemia after adjusting for multiple other risk factors [[59]]. These findings suggest that the presence of advanced nutritional wasting at ART start and a lack of nutritional recovery on treatment may predispose to the development of glucose intolerance. Notably, these results are similar to US studies showing lower limb fat in PLHIV is correlated with higher insulin resistance [[93], [94]]. Further studies are needed to understand whether a combination of poor nutritional status at the time of ART initiation, the demonstrated deleterious effects of some ART agents on adipose tissue function, and potentially other factors could predispose PLHIV in SSA to IFG or DM in the absence of obesity and other common risk factors (Figure 2). The prevalence of IFG and DM is high among PLHIV in SSA, but the marked variability in risk factors observed in prior studies underscores the need to further investigate the range of clinical phenotypes and the accompanying perturbations in bioenergetics pathways in a systematic manner.

3.4. Clinical Outcomes among SSA PLHIV with Comorbid Dysglycemia

Data on morbidity and mortality attributable to cardiovascular, microvascular, and macrovascular complications associated with comorbid dysglycemia in SSA PLHIV are scarce. In a study in Malawi of 281 patients with DM, 14% of whom were PLHIV, vision-threatening diabetic retinopathy was not associated with HIV status [[95]]. In South Africa, Pillay et al. [[96]] reported significantly higher nephropathy based on proteinuria (26% in PLHIV compared to 16% in HIV-negative) and neuropathy (50% in PLHIV compared to 44% in HIV-negative) in a chort of diabetic persons. This finding may have been related to poorer glucose control among PLHIV on either insulin or oral hypoglycemic agents. In contrast, they found higher prevalence of stage 2 or greater CKD based on KDOQI definitions in the HIV-negative cohort (42%) compared to PLHIV (31%), a finding that the authors partly attributed to the higher age range of the HIV-negative cohort (51–70 years) compared to PLHIV (41–60 years). A major limitation of this study was that HIV status was determined by self-report and was not directly confirmed.

3.5. Research Gaps and Priorities

While our review noted numerous gaps in the literature on dysglycemia in SSA PLHIV, we chose to highlight three specific areas that may form research priorities for future investigations. These are (i) the establishment of longitudinal PLHIV cohorts to improve our understanding of the causative associations between various risk factors and dysglycemia incidence, (ii) research into the interruption of progression from pre-DM to DM in SSA PLHIV, and (iii) studies on the clinical outcomes associated with comorbid HIV/DM.

While current studies show overlap between various risk factors that are associated with dysglycemia in SSA PLHIV, such associations remain correlative due to the use of cross-sectional and retrospective study designs in most analyses. An enhanced understanding of the causative risk factors may inform strategies to prevent dysglycemia in PLHIV. There is therefore a need for more longitudinal studies evaluating dysglycemia in SSA PLHIV cohorts. These may take the form of prospective observational studies that begin with a normoglycemic PLHIV cohort and follows them for a long period of time as has been done in some HIC settings [[42], [43]]. Understudied risk factors such as inflammation need to be evaluated, while the true effect of past and current ART agents, the duration of ART use, and the effect of known traditional risk factors (BMI, anthropometrics, fat distribution and nutrition) requires more investigation in this population.

The range of pre-DM prevalence (19% to 47%) was consistently high across our reviewed studies, representing an opportune area for research into interruption of disease progression in this cohort. Studies from the general population in HIC indicate that rates of pre-DM progression to overt DM may be decreased by 58% through the use of pharmacological interventions and lifestyle modification [[97][99]]. The extent to which these findings can be extrapolated to PLHIV populations, particularly in SSA, remains unknown. Nevertheless, these studies suggest a potential role for lifestyle interventions, anti-inflammatory therapy, and early use of antidiabetic agents (e.g., metformin) that could be investigated in SSA PLHIV populations.

There is a paucity of data on clinical outcomes among SSA PLHIV with DM, particularly with respect to CVD mortality and morbidity, and microvascular/macrovascular complications of DM and/or HIV. DM and HIV are both CVD risk factors, portending an elevated risk in patients with comorbid HIV/DM. Furthermore, studies suggest that control of DM, and other NCD comorbidities such as dyslipidemia and hypertension, is poorer compared to HIV-negative individuals [[96]], representing potentially worse outcomes in this cohort.

4. Conclusion

The prevalence of DM and pre-DM among PLHIV in SSA ranges from 1% to 26% and 19%–47%, respectively, reflecting an overall high burden of dysglycemia. However, variations in the study population assessed and diagnostic criteria limit firm conclusions. Older age, male gender, and an elevated BMI in the overweight/obese range are commonly associated risk factors for dysglycemia in SSA PLHIV. The interplay between HIV disease, ART, inflammation, and traditional risk factors in the pathophysiology of dysglycemia in SSA PLHIV is yet to be fully understood. There is a need for long-term longitudinal studies to elucidate the role of various risk factors in incident dysglycemia, future research in evaluating interventions to disrupt the progression of pre-DM to overt DM, and clinical outcome studies in comorbid DM/HIV patients in SSA.

References

  1. UNAIDSJoint United Nations Programme on HIV/AIDS (UNAIDS): Global AIDS Update2016Geneva, SwitzerlandJoint United Nations Programme on HIV/AIDS
  2. C. L. McDonaldJ. R. KaltmanCardiovascular disease in adult and pediatric HIV/AIDSJournal of the American College of Cardiology200954131185118810.1016/j.jacc.2009.05.0552-s2.0-7004908345719761941
  3. R. Martin-IguacelJ. M. LlibreN. Friis-MollerRisk of cardiovascular disease in an aging HIV population: where are we now?Current HIV/AIDS Reports201512437538710.1007/s11904-015-0284-62-s2.0-8494701714726423407
  4. T. T. BrownS. R. ColeX. LiAntiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort studyArchives of Internal Medicine2005165101179118410.1001/archinte.165.10.11792-s2.0-1934437305115911733
  5. A. C. Hernandez-RomieuS. GargE. S. RosenbergA. M. Thompson-PaulJ. SkarbinskiIs diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009–2010BMJ Open Diabetes Research & Care201751p. e00030410.1136/bmjdrc-2016-0003042-s2.0-8501166558728191320
  6. A. A. ButtK. McGinnisM. C. Rodriguez-BarradasHIV infection and the risk of diabetes mellitusAIDS200923101227123410.1097/QAD.0b013e32832bd7af2-s2.0-6765110270719444074
  7. K. SamarasPrevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapyJAIDS Journal of Acquired Immune Deficiency Syndromes200950549950510.1097/QAI.0b013e31819c291b2-s2.0-6544912782719223782
  8. A. E. SchutteD. van VuurenJ. M. van RooyenInflammation, obesity and cardiovascular function in African and Caucasian women from South Africa: the POWIRS studyJournal of Human Hypertension2006201185085910.1038/sj.jhh.10020652-s2.0-3375035561516855625
  9. R. AtunJ. I. DaviesE. A. M. GaleDiabetes in sub-Saharan Africa: from clinical care to health policyThe Lancet Diabetes & Endocrinology20175862266710.1016/S2213-8587(17)30181-X2-s2.0-8502179468928688818
  10. WHOUNAIDS Report on the Global AIDS Epidemic 20132013GenevaUNAIDS
  11. F. FarzadfarM. M. FinucaneG. DanaeiNational, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3·0 million participantsThe Lancet2011377976557858610.1016/S0140-6736(10)62038-72-s2.0-7995155099321295847
  12. M. M. FinucaneG. A. StevensM. J. CowanNational, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participantsThe Lancet2011377976555756710.1016/S0140-6736(10)62037-52-s2.0-7995155831821295846
  13. M. NgT. FlemingM. RobinsonGlobal, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013The Lancet2014384994576678110.1016/S0140-6736(14)60460-82-s2.0-8490688282224880830
  14. G. S. BloomfieldF. AleneziF. A. BarasaR. LumsdenB. M. MayosiE. J. VelazquezHuman immunodeficiency virus and heart failure in low- and middle-income countriesJACC: Heart Failure20153857959010.1016/j.jchf.2015.05.0032-s2.0-8493942687826251085
  15. F. C. ChowS. ReganS. FeskeJ. B. MeigsS. K. GrinspoonV. A. TriantComparison of ischemic stroke incidence in HIV-infected and non–HIV-infected patients in a US health care systemJAIDS Journal of Acquired Immune Deficiency Syndromes201260435135810.1097/QAI.0b013e31825c7f242-s2.0-8486428653222580566
  16. D. A. DuprezJ. NeuhausL. H. KullerInflammation, coagulation and cardiovascular disease in HIV-infected individualsPLoS One201279, article e4445410.1371/journal.pone.00444542-s2.0-8487123443622970224
  17. V. A. TriantH. LeeC. HadiganS. K. GrinspoonIncreased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus diseaseThe Journal of Clinical Endocrinology & Metabolism20079272506251210.1210/jc.2006-21902-s2.0-3425067122117456578
  18. C. DufouilL. RichertR. ThiébautDiabetes and cognitive decline in a French cohort of patients infected with HIV-1Neurology201585121065107310.1212/WNL.00000000000018152-s2.0-8494792375626156515
  19. R. K. MedapalliC. R. ParikhK. GordonComorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the veterans aging cohort studyJAIDS Journal of Acquired Immune Deficiency Syndromes201260439339910.1097/QAI.0b013e31825b70d92-s2.0-8486428331022592587
  20. E. J. WrightB. GrundL. A. CysiqueFactors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT strategic timing of antiretroviral treatment (START) trialHIV Medicine201516Supplement 19710810.1111/hiv.122382-s2.0-8492331995525711328
  21. A. G. TabákC. HerderW. RathmannE. J. BrunnerM. KivimäkiPrediabetes: a high-risk state for diabetes developmentThe Lancet201237998332279229010.1016/S0140-6736(12)60283-92-s2.0-8486230243222683128
  22. K. AnastosF. NdamageD. LuLipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan womenAIDS Research and Therapy201071p. 3410.1186/1742-6405-7-342-s2.0-7795686415020796311
  23. C. ChimbeteteC. MugglinT. ShamuNew-onset type 2 diabetes mellitus among patients receiving HIV care at Newlands clinic, Harare, Zimbabwe: retrospective cohort analysisTropical Medicine & International Health201722783984510.1111/tmi.128962-s2.0-8502024570328510998
  24. J. A. DaveE. V. LambertM. BadriS. WestG. MaartensN. S. LevittEffect of nonnucleoside reverse transcriptase inhibitor–based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patientsJAIDS Journal of Acquired Immune Deficiency Syndromes201157428428910.1097/QAI.0b013e318221863f2-s2.0-7996002786921602696
  25. S. E. IsaA. O. OcheA. R. Kang'ombeHuman immunodeficiency virus and risk of type 2 diabetes in a large adult cohort in Jos, NigeriaClinical Infectious Diseases201663683083510.1093/cid/ciw3812-s2.0-8499548956527307508
  26. G. B. KagarukiM. T. MayigeE. S. NgadayaMagnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regionsBMC Public Health2014141p. 90410.1186/1471-2458-14-9042-s2.0-8490797172225183300
  27. N. S. LevittN. PeerK. SteynIncreased risk of dysglycaemia in South Africans with HIV; especially those on protease inhibitorsDiabetes Research and Clinical Practice2016119414710.1016/j.diabres.2016.03.0122-s2.0-8497888075427423428
  28. E. MagangaL. R. SmartS. KalluvyaGlucose metabolism disorders, HIV and antiretroviral therapy among Tanzanian adultsPLoS One2015108, article e013441010.1371/journal.pone.01344102-s2.0-8494269348226287742
  29. I. M. MagodoroT. M. EsterhuizenT. ChiveseA cross-sectional, facility based study of comorbid non-communicable diseases among adults living with HIV infection in ZimbabweBMC Research Notes201691p. 37910.1186/s13104-016-2187-z2-s2.0-8497997650527484005
  30. E. M. ManuthuM. D. JoshiG. N. LuleE. KarariPrevalence of dyslipidemia and dysglycaemia in HIV infected patientsEast African Medical Journal2008851101710.4314/eamj.v85i1.960018543521
  31. A. E. MohammedT. Y. ShenkuteW. C. GebisaDiabetes mellitus and risk factors in human immunodeficiency virus-infected individuals at Jimma University specialized hospital, Southwest EthiopiaDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy2015819720610.2147/DMSO.S800842-s2.0-8493694498525926749
  32. E. MutimuraA. StewartP. RheederN. J. CrowtherMetabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapyJAIDS Journal of Acquired Immune Deficiency Syndromes200746445145510.1097/QAI.0b013e318158c0a62-s2.0-3604895204918077834
  33. J. NeginA. MartiniukR. G. CummingPrevalence of HIV and chronic comorbidities among older adultsAIDS201226S55S6310.1097/QAD.0b013e32835584592-s2.0-8486383108122781177
  34. W. NgatchouD. LemogoumE. NgaIncreased burden and severity of metabolic syndrome and arterial stiffness in treatment naïve HIV+ patients from CameroonVascular Health and Risk Management2013950951610.2147/VHRM.S423502-s2.0-8489003140824043942
  35. S. R. N. NoumegniJ. R. NansseuV. J. M. AmaInsulin resistance and associated factors among HIV-infected patients in sub-Saharan Africa: a cross sectional study from CameroonLipids in Health and Disease2017161p. 14810.1186/s12944-017-0543-128797289
  36. T. OniE. YoungbloodA. BoulleN. McGrathR. J. WilkinsonN. S. LevittPatterns of HIV, TB, and non-communicable disease multi-morbidity in peri-urban South Africa- a cross sectional studyBMC Infectious Diseases2015151p. 2010.1186/s12879-015-0750-12-s2.0-8492403352125595711
  37. S. KaramchandR. LeisegangM. SchomakerRisk factors for incident diabetes in a cohort taking first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapyMedicine2016959, article e284410.1097/MD.00000000000028442-s2.0-8496258734726945366
  38. J. V. BakerJ. NeuhausD. DuprezChanges in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infectionJAIDS Journal of Acquired Immune Deficiency Syndromes2011561364310.1097/QAI.0b013e3181f7f61a2-s2.0-7865068293520930640
  39. J. NeuhausD. R. Jacobs Jr.J. V. BakerMarkers of inflammation, coagulation, and renal function are elevated in adults with HIV infectionThe Journal of Infectious Diseases2010201121788179510.1086/6527492-s2.0-7795257199520446848
  40. N. I. WadaL. P. JacobsonJ. B. MargolickThe effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activationAIDS201529446347110.1097/QAD.00000000000005452-s2.0-8492228422025630041
  41. A. BalagopalD. M. AsmuthW. T. YangPre-cART elevation of CRP and CD4+ T-cell immune activation associated with HIV clinical progression in a multinational case–cohort studyJAIDS Journal of Acquired Immune Deficiency Syndromes201570216317110.1097/QAI.000000000000069626017661
  42. C. Béténé A DookoS. de WitJ. NeuhausInterleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapyJAIDS Journal of Acquired Immune Deficiency Syndromes201467553854610.1097/QAI.000000000000035425393940
  43. T. T. BrownK. TassiopoulosR. J. BoschC. ShikumaG. A. McComseyAssociation between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapyDiabetes Care201033102244224910.2337/dc10-06332-s2.0-7995171600020664016
  44. E. HurleyA. CoutsoudisJ. GiddyS. E. KnightE. LootsT. M. EsterhuizenWeight evolution and perceptions of adults living with HIV following initiation of antiretroviral therapy in a South African urban settingSouth African Medical Journal2011101964565021920157
  45. C. GuehiA. BadjéD. GabillardHigh prevalence of being overweight and obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano trialAIDS Research and Therapy2016131p. 1210.1186/s12981-016-0094-y2-s2.0-8495910561526925155
  46. J. CapeauV. BouteloupC. KatlamaTen-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatmentAIDS201226330331410.1097/QAD.0b013e32834e87762-s2.0-8485534607422089377
  47. S. De WitC. A. SabinR. WeberIncidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) studyDiabetes Care20083161224122910.2337/dc07-20132-s2.0-4864908531018268071
  48. P. ShankalalaC. JacobsS. BosomprahM. VinikoorP. KatayamoyoC. MicheloRisk factors for impaired fasting glucose or diabetes among HIV infected patients on ART in the Copperbelt Province of ZambiaJournal of Diabetes & Metabolic Disorders2017161p. 2910.1186/s40200-017-0310-x2-s2.0-8502438488628725640
  49. C. A. DimalaJ. AtashiliJ. C. MbuagbawA. WilfredG. L. MonekossoA Comparison of the diabetes risk score in HIV/AIDS patients on highly active antiretroviral therapy (HAART) and HAART-naïve patients at the Limbe Regional Hospital, CameroonPLoS One2016115, article e015556010.1371/journal.pone.01555602-s2.0-8498212422227195956
  50. F. TzurM. ChowersN. Agmon-LevinY. A. MekoriA. Y. HershkoIncreased prevalence of diabetes mellitus in a non-obese adult population: HIV-infected EthiopiansThe Israel Medical Association Journal2015171062062326665316
  51. E. CassolT. RossouwS. MalfeldCD14+ macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharideBMC Infectious Diseases2015151p. 43010.1186/s12879-015-1176-52-s2.0-8494520525626475133
  52. A. CanipeT. ChidumayoM. BlevinsA 12 week longitudinal study of microbial translocation and systemic inflammation in undernourished HIV-infected Zambians initiating antiretroviral therapyBMC Infectious Diseases2014141p. 52110.1186/1471-2334-14-5212-s2.0-8496431481525266928
  53. C. L. MonacoD. B. GootenbergG. ZhaoAltered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunodeficiency syndromeCell Host & Microbe201619331132210.1016/j.chom.2016.02.0112-s2.0-8496177782326962942
  54. J. R. KoetheM. BlevinsC. NyirendaNutrition and inflammation serum biomarkers are associated with 12-week mortality among malnourished adults initiating antiretroviral therapy in ZambiaJournal of the International AIDS Society2011141p. 1910.1186/1758-2652-14-192-s2.0-7995373277221477359
  55. B. McDonaldS. MoyoL. GabaitiriPersistently elevated serum interleukin-6 predicts mortality among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trialAIDS Research and Human Retroviruses201329799399910.1089/aid.2012.03092-s2.0-8487917031523590237
  56. M. J. SiednerJ. H. KimR. S. NakkuPersistent immune activation and carotid atherosclerosis in HIV-infected Ugandans receiving antiretroviral therapyThe Journal of Infectious Diseases2016213337037810.1093/infdis/jiv4502-s2.0-8496037510226347573
  57. M. BestawrosT. ChidumayoM. BlevinsIncreased systemic inflammation is associated with cardiac and vascular dysfunction over the first 12 weeks of antiretroviral therapy among undernourished, HIV-infected adults in Southern AfricaJournal of AIDS & Clinical Research201506310.4172/2155-6113.100043126038711
  58. I. SsinabulyaJ. KayimaC. LongeneckerSubclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in UgandaPLoS One201492, article e8953710.1371/journal.pone.00895372-s2.0-8489651986024586854
  59. G. PrayGodJ. ChangaluchaS. KapigaR. PeckJ. ToddS. FilteauDysglycemia associations with adipose tissue among HIV-infected patients after 2 years of antiretroviral therapy in Mwanza: a follow-up cross-sectional studyBMC Infectious Diseases2017171p. 10310.1186/s12879-017-2209-z2-s2.0-8501109255928137307
  60. D. Y. TesfayeS. KindeG. MedhinBurden of metabolic syndrome among HIV-infected patients in Southern EthiopiaDiabetes & Metabolic Syndrome: Clinical Research & Reviews20148210210710.1016/j.dsx.2014.04.0082-s2.0-8490226630324907175
  61. K. SamarasH. WandM. LawS. EmeryD. CooperA. CarrPrevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international diabetes foundation and adult treatment panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemiaDiabetes Care200730111311910.2337/dc06-10752-s2.0-3384602370217192343
  62. M. K. HellersteinC. GrunfeldK. WuIncreased de novo hepatic lipogenesis in human immunodeficiency virus infectionThe Journal of Clinical Endocrinology & Metabolism199376355956510.1210/jcem.76.3.84450112-s2.0-00274626518445011
  63. J. MacíasJ. GonzálezC. TuralPrevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patientsAIDS20142891279128710.1097/QAD.00000000000002482-s2.0-8492248109824614088
  64. M. SulyokM. MakaraZ. RupnikHepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: a cross-sectional studyEuropean Journal of Gastroenterology & Hepatology201527667968510.1097/MEG.00000000000003392-s2.0-8495763807625923943
  65. R. LombardiH. SambatakouI. MariolisD. CokkinosG. V. PapatheodoridisE. A. TsochatzisPrevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infectionDigestive and Liver Disease201648121471147710.1016/j.dld.2016.08.1172-s2.0-8499545185227623186
  66. L. LuziG. PerseghinG. TambussiIntramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophyAmerican Journal of Physiology-Endocrinology and Metabolism20032842E274E28010.1152/ajpendo.00391.200112388139
  67. M. TorrianiB. J. ThomasR. B. BarlowJ. LibrizziS. DolanS. GrinspoonIncreased intramyocellular lipid accumulation in HIV-infected women with fat redistributionJournal of Applied Physiology2006100260961410.1152/japplphysiol.00797.20052-s2.0-3364637103716223978
  68. O. A. LesiK. S. SoyebiC. N. EbohFatty liver and hyperlipidemia in a cohort of HIV-positive Africans on highly active antiretroviral therapyJournal of the National Medical Association2009101215115510.1016/S0027-9684(15)30828-22-s2.0-6524912574119378632
  69. P. Ongolo-ZogoN. Nkodo MbiaT. L. Mvogo MinkalaM. Biwole SidaC. KouanfackS. Nko AmveneLipodystrophie et stéatose hépatique échographique chez les patients VIH positifs sous multithérapie antirétrovirale (ARV) à Yaoundé (Cameroun)Bulletin de la Société de pathologie exotique2012105535336010.1007/s13149-012-0253-x2-s2.0-8487164448022886433
  70. J. R. KoetheC. A. JenkinsB. LauRising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and CanadaAIDS Research and Human Retroviruses2016321505810.1089/aid.2015.01472-s2.0-8495418619426352511
  71. B. YuhJ. TateA. A. ButtWeight change after antiretroviral therapy and mortalityClinical Infectious Diseases201560121852185910.1093/cid/civ1922-s2.0-8498326885425761868
  72. P. BacchettiB. GripshoverC. GrunfeldFat distribution in men with HIV infectionJAIDS Journal of Acquired Immune Deficiency Syndromes200540212113116186728
  73. C. GrunfeldM. SaagCofrancesco J Jr.Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophyAIDS201024111717172610.1097/QAD.0b013e32833ac7a22-s2.0-7795434881520502316
  74. J. PriceJ. HoyE. RidleyI. NyulasiE. PaulI. WoolleyChanges in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected menSexual Health201512324024810.1071/SH140842-s2.0-8493108028527470913
  75. V. M. CarterJ. F. HoyM. BaileyP. G. ColmanI. NyulasiA. M. MijchThe prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definitionHIV Medicine20012317418010.1046/j.1468-1293.2001.00073.x2-s2.0-003519956111737398
  76. P. C. TienS. R. ColeC. M. WilliamsIncidence of lipoatrophy and lipohypertrophy in the women’s interagency HIV studyJAIDS Journal of Acquired Immune Deficiency Syndromes200334546146610.1097/00126334-200312150-000032-s2.0-034419709714657755
  77. E. BernasconiK. BoubakerC. JunghansAbnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV cohort studyJAIDS Journal of Acquired Immune Deficiency Syndromes2002311505510.1097/00126334-200209010-000072-s2.0-003673711012352150
  78. M. SavesF. RaffiJ. CapeauFactors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapyClinical Infectious Diseases200234101396140510.1086/3398662-s2.0-003709381311981737
  79. M. GalliF. VegliaG. AngaranoGender differences in antiretroviral drug–related adipose tissue alterations: women are at higher risk than men and develop particular lipodystrophy patternsJAIDS Journal of Acquired Immune Deficiency Syndromes2003341586110.1097/00126334-200309010-000082-s2.0-004191414214501794
  80. L. KosmiskiD. KuritzkesJ. HamiltonFat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndromeHIV Medicine20034323524010.1046/j.1468-1293.2003.00151.x2-s2.0-004163106312859322
  81. Z. AbrahamsJ. A. DaveG. MaartensN. S. LevittChanges in blood pressure, glucose levels, insulin secretion and anthropometry after long term exposure to antiretroviral therapy in South African womenAIDS Research and Therapy2015121p. 2410.1186/s12981-015-0065-82-s2.0-8493856217026251665
  82. D. M. ZannouL. DenoeudK. LacombeIncidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in BeninAntiviral Therapy200914337138019474471
  83. J. J. van OosterhoutJ. MallewaS. KaundaStavudine toxicity in adult longer-term ART patients in Blantyre, MalawiPLoS One201277, article e4202910.1371/journal.pone.00420292-s2.0-8486483946622848696
  84. D. PodzamczerE. FerrerP. SanchezLess lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized studyJAIDS Journal of Acquired Immune Deficiency Syndromes200744213914710.1097/QAI.0b013e31802bf1222-s2.0-3384712656017106274
  85. D. NolanE. HammondA. MartinMitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapyAIDS20031791329133810.1097/00002030-200306130-000072-s2.0-003799908012799554
  86. E. HammondD. NolanI. JamesC. MetcalfS. MallalReduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6–12 months of commencing nucleoside reverse transcriptase inhibitor therapyAIDS200418581581710.1097/00002030-200403260-000152-s2.0-204243908815075519
  87. E. HammondE. McKinnonD. NolanHuman immunodeficiency virus treatment—induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequencesClinical Infectious Diseases201051559159910.1086/6557652-s2.0-7795582896420645860
  88. C. N. LumengJ. L. BodzinA. R. SaltielObesity induces a phenotypic switch in adipose tissue macrophage polarizationThe Journal of Clinical Investigation2007117117518410.1172/JCI298812-s2.0-3384602671217200717
  89. S. P. WeisbergD. McCannM. DesaiM. RosenbaumR. L. LeibelA. W. Ferrante Jr.Obesity is associated with macrophage accumulation in adipose tissueThe Journal of Clinical Investigation2003112121796180810.1172/JCI2003192462-s2.0-034823095814679176
  90. D. GaoM. MadiC. DingInterleukin-1β mediates macrophage-induced impairment of insulin signaling in human primary adipocytesAmerican Journal of Physiology-Endocrinology and Metabolism20143073E289E30410.1152/ajpendo.00430.20132-s2.0-8490719370124918199
  91. C. N. LumengS. M. DeyoungA. R. SaltielMacrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteinsAmerican Journal of Physiology-Endocrinology and Metabolism20072921E166E17410.1152/ajpendo.00284.20062-s2.0-3384600439616926380
  92. H. M. LawlerC. M. UnderkoflerP. A. KernC. EricksonB. BredbeckN. RasouliAdipose tissue hypoxia, inflammation, and fibrosis in obese insulin-sensitive and obese insulin-resistant subjectsThe Journal of Clinical Endocrinology & Metabolism201610141422142810.1210/jc.2015-41252-s2.0-8501127815026871994
  93. D. C. MynarcikM. A. McNurlanR. T. SteigbigelJ. FuhrerM. C. GelatoAssociation of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophyJAIDS Journal of Acquired Immune Deficiency Syndromes200025431232110.1097/00126334-200012010-000042-s2.0-003449235111114831
  94. G. MeiningerC. HadiganM. LaposataElevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistributionMetabolism200251226026610.1053/meta.2002.299992-s2.0-003618286311833059
  95. S. J. GloverP. I. BurgessD. B. CohenPrevalence of diabetic retinopathy, cataract and visual impairment in patients with diabetes in sub-Saharan AfricaBritish Journal of Ophthalmology201296215616110.1136/bjo.2010.1960712-s2.0-8485606415821515565
  96. S. PillayC. AldousF. MahomedA deadly combination - HIV and diabetes mellitus: where are we now?The South African Medical Journal20161064p. 5410.7196/SAMJ.2016.v106i4.99502-s2.0-8496204521627032854
  97. W. C. KnowlerE. Barrett-ConnorS. E. FowlerReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminThe New England Journal of Medicine2002346639340310.1056/NEJMoa0125122-s2.0-003703425711832527
  98. J. LindströmA. LouherantaM. MannelinThe Finnish diabetes prevention study (DPS): lifestyle intervention and 3-year results on diet and physical activityDiabetes Care200326123230323610.2337/diacare.26.12.32302-s2.0-034570749914633807
  99. A. RamachandranC. SnehalathaS. MaryThe Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)Diabetologia200649228929710.1007/s00125-005-0097-z2-s2.0-3184445206116391903
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5989168/fullTextXML. The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as human immunodeficiency virus infectious disease.